Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A …
Y Cao, L Xiang, F Qi, Y Zhang, Y Chen, X Zhou - EClinicalMedicine, 2022 - thelancet.com
Background Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease,
and among the non-invasive tests, controlled attenuation parameter (CAP) and liver stiffness …
and among the non-invasive tests, controlled attenuation parameter (CAP) and liver stiffness …
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver
disease and affects nearly a quarter of the global population. The objective of this work was …
disease and affects nearly a quarter of the global population. The objective of this work was …
The use of current knowledge and non‐invasive testing modalities for predicting at‐risk non‐alcoholic steatohepatitis and assessing fibrosis
M Kugelmas, M Noureddin, N Gunn, K Brown… - Liver …, 2023 - Wiley Online Library
There is ongoing recognition of the burden of non‐alcoholic fatty liver disease (NAFLD) and
non‐alcoholic steatohepatitis (NASH), with fibrosis being the most important histological …
non‐alcoholic steatohepatitis (NASH), with fibrosis being the most important histological …
Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population
J Rigor, A Diegues, J Presa, P Barata… - Postgraduate …, 2022 - Taylor & Francis
Objectives The burden of nonalcoholic fatty liver disease (NAFLD) is increasing, with an
estimated prevalence in Europe of 20–30%. Although most patients present with simple …
estimated prevalence in Europe of 20–30%. Although most patients present with simple …
Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index …
Methods A total of 560 patients (28 lean, 174 overweight, 229 obese, 89 severely obese, 40
morbidly obese) were included. Diagnostic performances and optimal cut-off values for FIB …
morbidly obese) were included. Diagnostic performances and optimal cut-off values for FIB …
The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Y Fouad, G Esmat, R Elwakil, S Zakaria… - Saudi Journal of …, 2022 - journals.lww.com
The landscape of chronic liver disease in Egypt has drastically changed over the past few
decades. The prevalence of metabolic-associated fatty liver disease (MAFLD) has risen to …
decades. The prevalence of metabolic-associated fatty liver disease (MAFLD) has risen to …
Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease
YJ Zhou, F Gao, WY Liu, GLH Wong… - Alimentary …, 2021 - Wiley Online Library
Summary Background Recently, Papatheodoridi et al proposed to refine the Baveno VI
elastography dual‐cutoffs and introduce an algorithm for the detection of compensated …
elastography dual‐cutoffs and introduce an algorithm for the detection of compensated …
Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult …
RO Moreira, CM Valerio… - … of Endocrinology and …, 2023 - SciELO Brasil
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously
known as Nonalcoholic fatty liver disease (NAFLD), is one of the most common hepatic …
known as Nonalcoholic fatty liver disease (NAFLD), is one of the most common hepatic …
Imaging-based non-invasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline
Conclusion: LSM from TE, SWE, and MRE show acceptable to outstanding accuracy for the
detection of liver fibrosis across various liver disease etiologies. Accuracy increased from F2 …
detection of liver fibrosis across various liver disease etiologies. Accuracy increased from F2 …
Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline
Keyur Patel1, Sumeet K Asrani2, Maria Isabel Fiel3, Deborah Levine4, Daniel H. Leung5,
Andres Duarte-Rojo6, Jonathan A. Dranoff7 Page 1 Accuracy of blood-based biomarkers for …
Andres Duarte-Rojo6, Jonathan A. Dranoff7 Page 1 Accuracy of blood-based biomarkers for …